INTRODUCTION: Smokers with a faster rate of nicotine metabolism, estimated using the ratio of 3'-hydroxycotinine (3-HC) to cotinine, have lower plasma nicotine levels and are more likely to relapse with 21 mg nicotine patch therapy, than smokers with slower rates of nicotine metabolism. Thus, faster metabolizers of nicotine may require a higher nicotine patch dose to achieve cessation. METHODS: This proof of concept randomized placebo-controlled trial evaluated the efficacy and safety of 8 weeks of 42 mg transdermal nicotine versus 21 mg, among 87 fast metabolizers of nicotine (3-HC/cotinine ≥ 0.18). RESULTS: After 1 week of treatment, an intent-to-treat (ITT) analysis showed that participants treated with 42 mg nicotine had significantly higher expired-air carbon monoxide (CO)-confirmed 24-hr abstinence (75% vs. 58.1%; OR = 3.21; 95% CI: 1.12-9.24, p = .03) but not 7-day abstinence (50% vs. 34.9%; OR = 2.02; 95% CI: 0.82-4.94, p = .13). After 8 weeks of treatment, ITT analysis showed that participants treated with 42 mg nicotine had marginally higher rates of CO-confirmed 24-hr abstinence (45.5% vs. 30.2%; OR = 2.32; 95% CI: 0.92-5.92, p = .08) but not 7-day abstinence (29.6% vs. 23.3%; OR = 1.52, 95% CI: 0.57-4.07, p = .41). Percent nicotine and cotinine replacement were significantly greater for 42 mg nicotine versus 21 mg (p < .005). There were no significant differences between treatment arms in the frequency of severe side effects and serious adverse events or blood pressure during treatment (p > .10). CONCLUSIONS: Further examination of the efficacy of 42 mg nicotine patch therapy for fast metabolizers of nicotine is warranted.
RCT Entities:
INTRODUCTION: Smokers with a faster rate of nicotine metabolism, estimated using the ratio of 3'-hydroxycotinine (3-HC) to cotinine, have lower plasma nicotine levels and are more likely to relapse with 21 mg nicotine patch therapy, than smokers with slower rates of nicotine metabolism. Thus, faster metabolizers of nicotine may require a higher nicotine patch dose to achieve cessation. METHODS: This proof of concept randomized placebo-controlled trial evaluated the efficacy and safety of 8 weeks of 42 mg transdermal nicotine versus 21 mg, among 87 fast metabolizers of nicotine (3-HC/cotinine ≥ 0.18). RESULTS: After 1 week of treatment, an intent-to-treat (ITT) analysis showed that participants treated with 42 mg nicotine had significantly higher expired-air carbon monoxide (CO)-confirmed 24-hr abstinence (75% vs. 58.1%; OR = 3.21; 95% CI: 1.12-9.24, p = .03) but not 7-day abstinence (50% vs. 34.9%; OR = 2.02; 95% CI: 0.82-4.94, p = .13). After 8 weeks of treatment, ITT analysis showed that participants treated with 42 mg nicotine had marginally higher rates of CO-confirmed 24-hr abstinence (45.5% vs. 30.2%; OR = 2.32; 95% CI: 0.92-5.92, p = .08) but not 7-day abstinence (29.6% vs. 23.3%; OR = 1.52, 95% CI: 0.57-4.07, p = .41). Percent nicotine and cotinine replacement were significantly greater for 42 mg nicotine versus 21 mg (p < .005). There were no significant differences between treatment arms in the frequency of severe side effects and serious adverse events or blood pressure during treatment (p > .10). CONCLUSIONS: Further examination of the efficacy of 42 mg nicotine patch therapy for fast metabolizers of nicotine is warranted.
Authors: J R Hughes; G R Lesmes; D K Hatsukami; R L Richmond; E Lichtenstein; D E Jorenby; J O Broughton; S P Fortmann; S J Leischow; J P McKenna; S I Rennard; W C Wadland; S A Heatley Journal: Nicotine Tob Res Date: 1999-06 Impact factor: 4.244
Authors: K A Perkins; C Lerman; C A Fonte; M Mercincavage; M L Stitzer; K N R Chengappa; A Jain Journal: Clin Pharmacol Ther Date: 2010-05-19 Impact factor: 6.875
Authors: Andrew A Strasser; Neal L Benowitz; Angela G Pinto; Kathy Z Tang; Stephen S Hecht; Steve G Carmella; Rachel F Tyndale; Caryn E Lerman Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-01-06 Impact factor: 4.254
Authors: Robert A Schnoll; Freda Patterson; E Paul Wileyto; Daniel F Heitjan; Alexandra E Shields; David A Asch; Caryn Lerman Journal: Ann Intern Med Date: 2010-02-02 Impact factor: 25.391
Authors: Marc E Mooney; Zhong-Ze Li; Sharon E Murphy; Paul R Pentel; Chap Le; Dorothy K Hatsukami Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-06 Impact factor: 4.254
Authors: Robert A Schnoll; Freda Patterson; E Paul Wileyto; Rachel F Tyndale; Neal Benowitz; Caryn Lerman Journal: Pharmacol Biochem Behav Date: 2008-10-31 Impact factor: 3.533
Authors: Jon O Ebbert; Herbert H Severson; Brian G Danaher; Neal L Benowitz; Darrell R Schroeder Journal: Nicotine Tob Res Date: 2015-05-14 Impact factor: 4.244
Authors: Patricia E Grebenstein; Danielle Burroughs; Samuel A Roiko; Paul R Pentel; Mark G LeSage Journal: Drug Alcohol Depend Date: 2015-04-07 Impact factor: 4.492
Authors: Dana M Carroll; Sharon E Murphy; Neal L Benowitz; Andrew A Strasser; Michael Kotlyar; Stephen S Hecht; Steve G Carmella; Francis J McClernon; Lauren R Pacek; Sarah S Dermody; Ryan G Vandrey; Eric C Donny; Dorothy K Hatsukami Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-02-12 Impact factor: 4.254
Authors: Matthew J Carpenter; Bianca F Jardin; Jessica L Burris; Amanda R Mathew; Robert A Schnoll; Nancy A Rigotti; K Michael Cummings Journal: Drugs Date: 2013-04 Impact factor: 9.546